ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development

Stock News

Yesterday

ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor agonist ASC36 and monthly next-generation GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered the clinical development stage. ASCLETIS-B expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q2 2026 for the ASC36 and ASC35 combo in obesity treatment.

"Based on these encouraging preclinical data, we believe the ASC36 and ASC35 combination has the potential to achieve more significant weight loss than monotherapy in obese patients," said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. "Our growing pipeline demonstrates our platform's capability in designing, optimizing, and developing ultra-long-acting once-monthly subcutaneous peptide therapies."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1190620025"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190620025\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1190620025?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190620025","market":"fut","top_or_hot":-1,"title":"ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development","media":"Stock News","content":"<p>ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor agonist ASC36 and monthly next-generation GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered the clinical development stage. ASCLETIS-B expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q2 2026 for the ASC36 and ASC35 combo in obesity treatment.</p>\n<p>\"Based on these encouraging preclinical data, we believe the ASC36 and ASC35 combination has the potential to achieve more significant weight loss than monotherapy in obese patients,\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. \"Our growing pipeline demonstrates our platform's capability in designing, optimizing, and developing ultra-long-acting once-monthly subcutaneous peptide therapies.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-13 10:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor agonist ASC36 and monthly next-generation GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered the clinical development stage. ASCLETIS-B expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q2 2026 for the ASC36 and ASC35 combo in obesity treatment.</p>\n<p>\"Based on these encouraging preclinical data, we believe the ASC36 and ASC35 combination has the potential to achieve more significant weight loss than monotherapy in obese patients,\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. \"Our growing pipeline demonstrates our platform's capability in designing, optimizing, and developing ultra-long-acting once-monthly subcutaneous peptide therapies.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1190620025","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190620025","pubTimestamp":1763001025,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","BK1161":"生物科技","BK1574":"生物医药B类股","01477":"欧康维视生物-B","01672":"歌礼制药-B"},"translate_title":"ASC36和ASC35组合进入临床开发，歌礼-B(01672)再次涨超4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01672":1},"content_text":"ASCLETIS-B (01672) surged over 4% again, trading at HK$11.68 by the latest update, up 3.55%, with a turnover of HK$8.54 million. The company announced that its monthly next-generation amylin receptor agonist ASC36 and monthly next-generation GLP-1R/GIPR dual-target agonist ASC35 combination therapy has entered the clinical development stage. ASCLETIS-B expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q2 2026 for the ASC36 and ASC35 combo in obesity treatment.\n\"Based on these encouraging preclinical data, we believe the ASC36 and ASC35 combination has the potential to achieve more significant weight loss than monotherapy in obese patients,\" said Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B. \"Our growing pipeline demonstrates our platform's capability in designing, optimizing, and developing ultra-long-acting once-monthly subcutaneous peptide therapies.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}